Abstract
The use of glaucoma medications containing the preservative benzalkonium chloride (BAK) is associated with a number of ocular symptoms including ocular surface disease and dry eye syndrome. These are debilitating conditions and current strategies of therapeutic escalation
Abstract
The use of glaucoma medications containing the preservative benzalkonium chloride (BAK) is associated with a number of ocular symptoms including ocular surface disease and dry eye syndrome. These are debilitating conditions and current strategies of therapeutic escalation
compound the problem. The effects are greater in sensitive patients and rises as the number of eye drops used increases. Preservative-free antiglaucoma medications are available and should be considered in patients with primary dry eye syndrome, ocular allergy, meibomian gland dysfunction, contact lens wearing, corneal and conjunctival adverse reactions to antiglaucoma medication and pre-operative to trabeculectomy. The importance of elevated diurnal variations in intraocular pressure (IOP) in glaucoma patients was also considered.
Support: The publication of this article was funded by Santen Oy. The views and opinions expressed are those of the author and not necessarily those of Santen Oy.
To view the full article in PDF or eBook formats, please click on the icons above.
